Recombinant Listeria monocytogenes strains induce strong cellular immune responses and may prove useful for antigen delivery for the vaccination of humans. However, the genetic systems currently available for the stable expression of recombinant antigens by L. monocytogenes rely on the use of antibiotic resistance genes. We report on a derivative, pPL2dalGlnA, of the Listeria monocytogenes pPL2 integration vector that completely lacks drug resistance genes. The selectable markers in pPL2dalGlnA are glutamine synthetase (GlnA) and alanine racemase (Dal). This novel vector was stably maintained in auxotropic L. monocytogenes strains that normally require D-alanine. The pPL2dalGlnA vector also partially restored the ability of an L. monocytogenes ⌬dal ⌬dat strain to colonize the spleens and livers of infected mice. A novel, highly attenuated strain of L. monocytogenes with quadruple deletions was also engineered by deleting the L. monocytogenes actA and plcB virulence genes from a ⌬dal ⌬dat strain. Infection of mice with recombinants of this mutant strain that express the antigen from pPL2dalGlnA were shown to elicit CD8 ؉ T-cell responses to human immunodeficiency virus Tat. This vector system is thus useful for stable antigen expression and vaccination studies.
Listeria monocytogenes is a gram-positive bacterium and facultative intracellular parasite of humans and animals. The bacterium expresses a hemolysin (LLO) that enables it to invade and replicate within the cytosol of eukaryotic cells. Similar to the proteins produced by viral infection, the proteins produced by cytosolic L. monocytogenes are processed and presented to the vertebrate immune system by the endogenous major histocompatibility complex (MHC) class I antigen presentation pathway. Peptide-loaded class I MHC molecules that reach the surface of specialized antigen-presenting cells prime naïve CD8
ϩ T cells to expand in number and differentiate into mature long-lived memory cell populations. Several endogenous L. monocytogenes antigens are known to trigger CD8 ϩ T-cell responses that can protect mice from subsequent infections (15) . In addition, recombinant proteins expressed by L. monocytogenes can access the endogenous MHC class I presentation pathway and prime protective CD8 ϩ T-cell responses (12, 17) . Thus, recombinant L. monocytogenes strains show promise as vaccination vehicles for the generation of CD8 ϩ T-cell responses in humans.
The widespread use of live organisms for antigen delivery in humans currently faces several hurdles. These include the need to engineer attenuated strains that safely and stably express and deliver the foreign antigens of interest. To date, most systems used for recombinant antigen expression in L. monocytogenes have used plasmids with antibiotic resistance markers either to maintain the antigen-encoding plasmids in the cytoplasm of the bacteria or as selectable markers to aid with the isolation of chromosomal integrants of the antigen expression construct (8, 9, 12, 16, 17) . While these strategies demonstrate the ability of recombinant L. monocytogenes strains to elicit cell-mediated immune responses to viral and cancer antigens, the currently used plasmid vectors are unstable without constant selection pressure and may be lost from the vaccine bacterial strain during replication within the host. Furthermore, vaccine strains that use antibiotic resistance markers for selection purposes have the potential to transmit resistance genes to other pathogens, undermining the therapeutic usefulness of the respective antibiotics.
The development of genetic systems to integrate antigen expression constructs into the L. monocytogenes genome circumvents several of the problems associated with plasmid instability. However, construction of such vaccine strains traditionally required the time-consuming process of allelic exchange. More recently, a novel integration vector has been developed to permit chromosomal insertions in a single step. This vector, pPL2, has previously been used to stably integrate a variety of genes at a specific site in the chromosome of Listeria monocytogenes (13) . However, as with other genetic systems, the engineering of recombinant strains with pPL2 has entailed the use of antibiotic resistance genes as selectable markers.
Here we report on the development of a second-generation pPL2 vector that can be used to engineer recombinant L. monocytogenes vaccine strains in the complete absence of antibiotic resistance markers. This new vector, pPL2dalGlnA, is stably maintained in L. monocytogenes strains cultured in broth and can be used to express antigens. Furthermore, CD8
ϩ Tcell responses specific for human immunodeficiency virus (HIV) Tat antigens were generated upon infection with a novel attenuated L. monocytogenes vaccine strain expressing the HIV Tat antigen from pPL2dalGlnA. Hence, the novel genetic system developed here may prove useful for the vaccination of humans. alanine (10403S::pPL2dalGlnA). Backdilutions were repeated at ϳ12-h intervals for a total of 13 to 18 passages. The OD 600 of the final culture was measured and was used to estimate the bacterial numbers in the culture. On the basis of this estimate, volumes equivalent to ϳ200 CFU were plated onto BHI agar plates and BHI agar plates supplemented with chloramphenicol or D-alanine at the concentrations indicated above. The numbers of CFU recovered from nonselective plates (BHI agar for 10403S::pPL2 or BHI plus D-alanine for 10403S:: pPL2dalGlnA) were compared to the number recovered from selective plates to estimate the frequency of pPL2dalGlnA loss.
Animal infections. The competitive index (CI) assay measures the relative abilities of two strains to survive and replicate in the tissues of infected mice. CI values were determined as detailed previously (2), with the exception that output CI values were adjusted to the ratio of the number of test strains input/number of control strains input. The measured input ratios were between 1.1 and 1.4 for all experiments. Briefly, mice were infected intravenously (i.v.) with a total dose of 2 ϫ 10 5 CFU that was an estimated 1:1 input ratio of strain DP-L3903 and either 10403S::pPL2 or 10403S::pPL2dalGlnA. At 72 h after infection, the mice were killed, their livers were harvested and homogenized in 0.2% Nonidet P-40, and serial dilutions were plated on LB agar without erythromycin (Erm). After growth at 37°C, ϳ60 individual colonies were patched from these plates onto plates supplemented with 1 g/ml Erm. The ratios of the Erm r wild-type strain/ Erm s test strains (10403S::pPL2 and 10403S::ppl2dalGlnA) were then calculated on the basis of the number of patched colonies that grew on LB agar-Erm. This ratio was divided by the input ratio to determine the adjusted CI value for each of the three to five C57BL/6 mice used per experiment.
We also investigated the ability of an L. monocytogenes ⌬dal ⌬dat strain complemented with pPL2dalGlnA (L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA) to replicate and persist in the organs of mice after monotypic infection. The bacteria were grown to log phase (OD 600 , ϳ0.1) in tryptic soy broth medium supplemented with 100 g/ml D-alanine and diluted into PBS. C57BL/6 mice were infected with an immunizing dose of wild-type L. monocytogenes strain 10403S (5,000 CFU) or with 10 4 or 10 6 CFU of L. monocytogenes ⌬dal ⌬dat or L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA. The livers and spleens were harvested at 36 h postinfection (hpi), and serial dilutions of the lysates from these organs were plated on LB agar (strains 10403S and L. monocytogenes ⌬dal ⌬dat::dalGlnA) or LB agar plus 100 g/ml D-alanine (L. monocytogenes ⌬dal ⌬dat) to enumerate the bacterial burdens.
Cloning of SIV Nef and HIV Tat into pPL2dalGlnA. An antigen expression cassette was made by cloning FLAG-tagged simian immunodeficiency virus (SIV) Nef (deleted of its first 11 amino acids) and vesicular stomatitis virus (VSV)-tagged HIV Tat downstream of DNA containing the L. monocytogenes actA and hly promoter signal sequences, respectively, in pUC19. The KpnI-PstI fragment encoding these genes was then subcloned into pPL2dalGlnA and electroporated into the E. coli strains from which glnA was deleted. Recombinant colonies were selected on nutrient broth agar without glutamine and identified by PCR analysis. Plasmid DNA (ϳ3 g) from a positive clone was electroporated into the ⌬actA-plcB derivative of L. monocytogenes ⌬dal ⌬dat described above to generate the recombinant vaccine strain, L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB Nef Tat.
Immunoblots. The recombinant L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB Nef Tat strain and the control L. monocytogenes ⌬dal ⌬dat strain were grown in BHI broth (supplemented with D-alanine for L. monocytogenes ⌬dal ⌬dat) at 30°C overnight. The overnight cultures were diluted 1:20 and grown at 36°C for 4 h. After centrifugation, the proteins in the supernatant fractions of these cultures were precipitated with trichloroacetic acid (TCA). The TCA-precipitated proteins from 1 ml of supernatant were dissolved in sample buffer (62.5 mM Tris-Cl, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 5% ␤-mercaptoethanol, 0.1% bromophenol blue) and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred to nitrocellulose membranes, blocked in Blotto buffer (1% Tween 20, 5% nonfat milk in PBS) for 2 h, incubated with a primary anti-tag antibody (anti-VSV antibody for Tat protein and anti-FLAG antibody for Nef protein) at 4°C overnight and then with horseradish peroxidase-labeled immunoglobulin G for 1 h at room temperature, and detected with an enhanced chemiluminescence Western blotting analysis system and by exposure to film.
Immunization and ELISPOT assay. For the mouse immunizations, 6-to 8-week-old female BALB/c mice were inoculated i.v. with 2 ϫ 10 7 CFU of the L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB Nef Tat strain. After 10 days, splenocyte suspensions were prepared by pressing the tissue through a nylon mesh screen, followed by lysis of red blood cells with ACK lysis buffer (Invitrogen). Ninetysix-well enzyme-linked immunospot (ELISPOT) assay plates (Millipore, Bedford, MA) were coated with anti-mouse gamma interferon (IFN-␥) capture antibody (1:60 in PBS; R&D Systems) and incubated overnight at 4°C. On the VOL. 15, 2008 INTEGRATIONAL VECTOR pPL2dalGlnA FOR LISTERIA 1415
on September 6, 2017 by guest http://cvi.asm.org/ second day, the plates were washed and blocked for 2 h with RPMI 1640 containing 10% fetal bovine serum (Genimi BioProducts) and 1% of a 10,000-U/ml penicillin-streptomycin solution. Suspensions containing 5 ϫ 10 5 splenocytes in RPMI 1640 were added to each well and were stimulated in duplicate, with or without 25 g/ml of a complete set of HIV type 1 clade B Tat synthetic 15-amino-acid-long peptides, each of which overlapped by 11 amino acids (AIDS Research and Reference Reagent Program), or 25 g/ml of concanavalin A (Sigma Chemical Co.). After incubation at 37°C in a 5% CO 2 incubator for 24 h, the plate was washed and incubated with biotinylated anti-mouse IFN-␥ detection antibody (1:60 in 1% bovine serum albumin; R&D Systems) and incubated overnight at 4°C. The wells were then incubated with streptavidin-conjugated alkaline phosphatase (1:60 in 1% bovine serum albumin) for 2 h at room temperature, washed with PBS, and incubated with 5-bromo-4-chloro-3-indolyl phosphate substrate to develop the color. The spots were counted with an automated ELISPOT reader (Cellular Technology, Ltd., Shaker Heights, OH).
RESULTS AND DISCUSSION
Engineering of pPL2dalGlnA. L. monocytogenes strains that retain the ability to invade and replicate in the host cell cytosol also retain immunogenicity and are showing promise as vaccine delivery vehicles (5). D-Alanine is an essential component of bacterial peptidoglycan and is also incorporated into teichoic acids. In L. monocytogenes, D-alanine is produced from L-alanine by an alanine racemase (Dal) and from D-glutamic acid plus pyruvate by a D-amino acid transferase (Dat). L. monocytogenes strains from which both dal and dat are deleted (⌬dal ⌬dat strains) thus require exogenous D-alanine for continued replication. Furthermore, since only trace quantities of D-alanine are produced by mammals, the replication of L. monocytogenes ⌬dal ⌬dat is truncated in infected cells or mice (20) . However, L. monocytogenes ⌬dal ⌬dat strains retain the ability to access the host cell cytosol and were shown to generate CD8
ϩ T-cell responses to L. monocytogenes antigens (20) . Given previous work that showed the utility of the dal gene as a selectable marker for the maintenance of plasmids in a D-alanine-auxotrophic Bacillus subtilis strain (7), we reasoned that dal might similarly be used for selection of the pPL2 integrational vector in L. monocytogenes ⌬dal ⌬dat. We thus first replaced the gram-positive bacterial chloramphenicol resistance (cat) gene with the L. monocytogenes dal gene to create pPL2dal (Fig. 1A) . pPL2dal was then mated into an L. monocytogenes ⌬dal ⌬dat strain and selected for growth on BHI agar plates lacking D-alanine supplementation. Several colonies were obtained and were shown by PCR to have integrated pPL2dal into the appropriate tRNA Arg locus (data not shown). These data confirmed the utility of dal as a selectable marker for use in L. monocytogenes ⌬dal ⌬dat strains.
We next sought to replace the gram-negative bacterial antibiotic resistance marker (cat) used for the maintenance of pPL2dal in E. coli. We also considered using dal for selection in E. coli strains that require D-alanine due to flp recombinasemediated disruption of the alanine racemase and D-amino acid dehydrogenase (alr::frt dadX::frt). However, such strains give rise to pseudorevertants on medium not supplemented with D-alanine, which may complicate the engineering of antigenexpressing plasmids. Therefore, we instead replaced the gramnegative bacterial cat gene with the E. coli gene for glutamine synthetase (glnA) to generate plasmid pPL2dalGlnA (Fig. 1B) . The resulting pPL2dalGlnA vector entirely lacks antibiotic resistance genes but retains a replication origin for gram-negative bacteria (p15A ori), an origin of transfer for mating (oriT from the conjugative plasmid RP4), a multicloning site, and the integrase gene (int) and phage attachment site (attP) from phage PSA. We next engineered glutamine-auxotophic E. coli strains by deleting glutamine synthetase and its promoter from E. coli SURE and MG1655. These ⌬glnA strains failed to grow on autoclaved nutrient broth, which is deficient in glutamine (3). However, transformation of either strain with pPL2dalGlnA restored their growth on glutamine-free medium, confirming that this system can be used to engineer antigen expression cassettes in pPL2dalGlnA.
Stability of pPL2dalGlnA integration in L. monocytogenes ⌬dal ⌬dat. Similar to pPL2dal, pPL2dalGlnA restored the ability of L. monocytogenes ⌬dal ⌬dat to grow on selective (Dalanine-deficient) medium. To determine the stability of pPL2dlaGlnA integration in the absence of selective pressure, we repeatedly passaged the complemented L. monocytogenes ⌬dal ⌬dat strain under nonselective conditions. When colonies were plated after 13 to 18 serial passages in the absence of selective pressure, 96 to 100% of the colonies recovered on nonselective BHI agar plates (supplemented with D-alanine) were also recovered on selective (nonsupplemented) BHI agar FIG. 1. Maps of plasmid vectors pPL2dal (A) and pPL2dalGlnA (B) engineered in this study. Both plasmids were derived from the pPL2 vector (13) , which can be integrated in a single step into the chromosome of L. monocytogenes. The plasmids were continually selected in appropriate auxotrophic E. coli ⌬glnA and L. monocytogenes ⌬dal ⌬dat strains. pPL2dal retains an antibiotic resistance marker for chloramphenicol resistance (cat) in gram-negative bacteria, while pPL2dalGlnA lacks all antibiotic resistance markers.
plates. These data are consistent with previously published data on the stability of pPL2 integration (13) and indicate that the integrated pPL2dalGlnA vector is highly stable even in the absence of selection.
pPL2dalGlnA only partially complements the virulence of L. monocytogenes ⌬dal ⌬dat. To evaluate the effects of pPL2dalGlnA on the growth and virulence of the L. monocytogenes strains, we first compared the growth rate of an L. monocytogenes ⌬dal ⌬dat strain with integrated pPL2dalGlnA (L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA) to that of wildtype L. monocytogenes parental strain 10403S and a pPL2 integrant of 10403S ( Fig. 2A) . Equal numbers of each bacterial strain were diluted in parallel from overnight cultures into nonsupplemented BHI broth, and the growth of the respective strains was measured by hourly readings of the OD from each culture. As shown in Fig. 2 , the growth rates of the three bacterial strains were identical. In the absence of pdPL2dalGlnA or medium supplemented with D-alanine, L. monocytogenes ⌬dal ⌬dat showed no growth at all (data not shown). Thus, these data suggest that the expression of alanine racemase from the integrated pPL2dalGlnA vector fully complements the growth of L. monocytogenes ⌬dal ⌬dat in culture. We thus next used a CI assay to quantify the effects of pPL2dalGlnA integration on bacterial growth in infected C57BL/6 mice. For these experiments, groups of three to five mice each were infected with equal ratios of the pPL2 integrant or the pPL2dalGlnA integrant and a wild-type Erm-resistant L. monocytogenes 10403S strain (strain DP-L3903). At 72 h after i.v. infection, homogenates of tissues were harvested from the infected mice and plated on BHI broth alone or BHI broth supplemented with 1 g/ml Erm. On the basis of the colony counts, the ratios of the CI of the Erm-sensitive strain (the pPL2 integrant of strain 10403S or L. monocytogenes ⌬dal ⌬dat:: pPL2dalGlnA) to the CI of the Erm-resistant strain (10403S) from the liver of each mouse were determined (Fig. 2B) . In two of two experiments, the pPL2 integrant of 10403S showed only a slight competitive disadvantage (mean CI ratio, ϳ0.5) relative to that of wild-type strain 10403S. In contrast, the L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA strain showed a more substantial reduction in its ability to compete for growth in vivo (mean CI ratio, ϳ0.01). These data suggest that alanine racemace is not sufficient for full complementation of the growth of L. monocytogenes ⌬dal ⌬dat during whole-animal infection, and that the dat deletion restricts the growth of these bacteria. In addition, one may speculate that the L-alanine substrate for alanine racemase may be limiting at sites of L. monocytogenes replication in infected mice.
It is known that L. monocytogenes must persist in the tissues of infected mice for over 24 h in order to generate robust protective T-cell responses (14) . We thus also determined whether the attenuated L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA strain was capable of persisting for Ͼ24 h after monotypic infection of C57BL/6 mice. The results of this experiment are shown in Table  1 . In mice given doses containing as many as 10 6 L. monocytogenes ⌬dal ⌬dat bacteria, we failed to recover any CFU from infected spleens and livers by 36 hpi. Conversely, when the mice were given the L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA strain, bacteria were still recovered from the tissues of infected mice at this time point. With the low-dose infection (10 4 CFU), the rate of recovery of L. monocytogenes ⌬dal ⌬dat::pPL2dalGlnA bacteria was ϳ20-to 250-fold less than that seen with low-dose infection with wild-type strain 10403S. However, when the mice were inoculated with a higher dose of L. monocytogenes ⌬dal ⌬dat:: pPL2dalGlnA (10 6 CFU), bacteria were recovered in numbers only two-to fourfold lower than the numbers of wild-type strain 10403S recovered. These data indicate that the stable integration of pPL2dalGlnA into the chromosome of L. monocytogenes ⌬dal ⌬dat restores the ability to establish infection of mouse tissues that persists beyond 24 hpi. These data further suggest that pPL2dalGlnA-based antigen expression constructs engineered in However, growth of the complemented strain was reduced by only ϳ100-fold. We thus sought to generate a more highly attenuated vaccine strain. L. monocytogenes mutants that individually lacked the actA or the plcB virulence gene are defective for bacterial cell-cell spread and had ϳ10,000-fold and 100-fold reduced growth, respectively, by the CI assay (11, 18) . In addition, the attenuated L. monocytogenes 10403S from which the actA and plcB genes were deleted has also been studied in a phase I dose escalation safety study of oral delivery with 20 healthy human volunteers (1) . Doses up to 10 9 CFU were well tolerated. In the previous study, there were no serious adverse events from systemic infection, suggesting that attenuated L. monocytogenes ⌬actA-plcB is a reasonable strain for use as a start in the engineering of a human vaccine vector. Thus, to generate a more highly attenuated strain for use with pPL2dalGlnA-based vaccines, we deleted both of these linked pathogenicity genes from an L. monocytogenes ⌬dal ⌬dat strain. The resulting strain is defined as L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB.
Antigen expression and immunization with pPL2dalGlnA. To demonstrate the usefulness of pPL2dalGlnA and L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB for the expression and delivery of foreign antigens, we engineered constructs for the expression of the SIV Nef and the HIV Tat antigens (Fig. 3A) . Genes for these antigens were cloned downstream of DNA containing the L. monocytogenes actA and hly promoters, respectively, and introduced into L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB. Culture supernatants from L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB transformants contained both the Nef and the Tat proteins (Fig. 3B) , as detected by immunoblotting. When it was used to immunize BALB/c mice, the recombinant L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB Nef Tat strain elicited a clear response to the set of HIV type 1 Tat peptides (Fig. 3C ). An IFN-␥ ELISPOT assay revealed that ϳ1/10,000 splenocytes responded to the Tat peptide at 10 days after immunization (Fig. 3C) . Thus, we conclude that the pPL2dalGlnA vector system will be useful for the generation of safe vaccine strains of L. monocytogenes by use of the novel strain L. monocytogenes ⌬dal ⌬dat ⌬actA-plcB or other derivatives of L. monocytogenes ⌬dal ⌬dat.
In conclusion, we have developed a novel genetic system for the stable expression of recombinant antigens from attenuated L. monocytogenes in the absence of antibiotic resistance genes. We believe that our system is an improvement over that of Verch et al., who recently used dal to maintain plasmids in auxotrophic D-alanine-requiring E. coli and L. monocytogenes bacterial strains (21) . Our novel system is instead based on modifications of the integrational vector pPL2. Like the parental pPL2 vector, pPL2dalGlnA is stably maintained in L. monocytogenes even without selection. In addition, given the paucity of D-alanine in mammalian tissues, pPL2dalGlnA 
